Supernus Pharmaceuticals Hits New 52-Week High of $47.65

Supernus Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 47.65 on September 23, 2025. This achievement underscores the company's strong performance in the pharmaceuticals and biotechnology sector, where it has demonstrated a remarkable one-year performance of 78.81%, significantly outpacing the S&P 500's 17.38% during the same period.
With a market capitalization of USD 2,569 million, Supernus operates as a small-cap entity within its industry. The company's price-to-earnings (P/E) ratio stands at 29.00, reflecting its valuation relative to earnings. Additionally, Supernus maintains a price-to-book ratio of 2.42, indicating its market value compared to its book value.

Despite a dividend yield of 0.00%, the company showcases a solid return on equity of 6.51% and a debt-to-equity ratio of -0.48, suggesting a strong financial position. The stock's previous 52-week low was recorded at USD 29.16, highlighting the significant upward movement in its price. This performance positions Supernus Pharmaceuticals as a noteworthy player in the market.